Dr. Pal is an established serial entrepreneur with more than two decades of experience in the pharmaceutical and biotechnology industries. He has spent much of his career within successful, early-stage companies where he held roles of increasing responsibility. Most recently, Dr. Pal was the Founder and CEO of Mnemosyne Pharmaceuticals (now known as Cadent Therapeutics), a neuroscience drug discovery company which partnered with Novartis in 2014. Prior to his work with Mnemosyne, he was Co-Founder and SVP of Research and Development at Corbus Pharmaceuticals (Nasdaq: CRBP), a clinical-stage company developing novel drugs for scleroderma and cystic fibrosis.
Earlier in his career, Dr. Pal served as Vice President of Chemistry at Neogenesis, a novel screening and chemistry technologies company acquired by Schering Plough-Merck, and as Director of Chemistry at the oncology startup Mitotix which was later acquired by GPC Biotech. He has also previously served as a Principal at PureTech Ventures (now PureTech Health). Kollol began his scientific career at Boehringer Ingelheim, where he was a member of the research team that developed Viramune, the first non-nucleoside reverse transcriptase inhibitor for the treatment of HIV/AIDS.
Dr. Pal holds a PhD in organic chemistry from the Massachusetts Institute of Technology (MIT), an MBA from the MIT Sloan School of Management, and a bachelor’s degree in chemistry from Cornell University.